Ruxolitinib Therapy Followed by Reduced Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis - Myeloproliferative Disorders Research Consortium 114 study.
Biol Blood Marrow Transplant. 2018 Sep 08;:
Am J Gastroenterol. 2018 Aug 30;:
Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practice.
Thromb Res. 2018 May 03;167:6-8
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
JAMA Oncol. 2018 Mar 08;:
Leuk Res. 2018 Feb 20;68:22-28
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
Haematologica. 2016 12;101(12):e482-e484
Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
Blood Adv. 2017 Sep 12;1(20):1729-1738
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Lancet Haematol. 2017 Dec 20;:
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.
Oncotarget. 2017 Oct 24;8(51):89256-89268
Impact of comorbidities constituting the HCT-CI score on the outcome of patients undergoing allogeneic HCT for AML.
Eur J Haematol. 2017 Nov 23;: